{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:21:11Z","timestamp":1791166871376,"version":"4.1.0"},"reference-count":184,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3075,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1002\/hep.21627","type":"journal-article","created":{"date-parts":[[2007,3,28]],"date-time":"2007-03-28T21:47:21Z","timestamp":1175118441000},"page":"1056-1075","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":473,"title":["Management of hepatitis B"],"prefix":"10.1097","volume":"45","author":[{"given":"Jay H.","family":"Hoofnagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Doo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Jake","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-26-20241201","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2006.04.025","article-title":"Native hepatitis B virions and capsids visualized by electron cryomicroscopy","volume":"22","author":"Dryden","year":"2006","journal-title":"Molecular Cell"},{"key":"R3-26-20241201","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1053\/gast.2001.22454","article-title":"Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection","volume":"120","author":"Doo","year":"2001","journal-title":"Gastroenterology"},{"key":"R4-26-20241201","doi-asserted-by":"crossref","first-page":"12242","DOI":"10.1128\/JVI.79.19.12242-12252.2005","article-title":"Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection","volume":"79","author":"Le Mire","year":"2005","journal-title":"J Virol"},{"key":"R5-26-20241201","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"R6-26-20241201","doi-asserted-by":"crossref","first-page":"11652","DOI":"10.1073\/pnas.1635109100","article-title":"Hepatocyte turnover during resolution of a transient hepadnaviral infection","volume":"100","author":"Summers","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-26-20241201","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"key":"R8-26-20241201","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","article-title":"Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice","volume":"91","author":"Guidotti","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-26-20241201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","article-title":"Noncytolytic control of viral infections by the innate and adaptive immune response","volume":"19","author":"Guidotti","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"R10-26-20241201","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/JVI.76.6.2617-2621.2002","article-title":"Interferon\u2010regulated pathways that control hepatitis B virus replication in transgenic mice","volume":"76","author":"Guidotti","year":"2002","journal-title":"J Virol"},{"key":"R11-26-20241201","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T\u2010lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat Med"},{"key":"R12-26-20241201","first-page":"1044","article-title":"Hepatitis B virus infection in patients with idiopathic liver disease","volume":"13","author":"Liang","year":"1991","journal-title":"HEPATOLOGY"},{"key":"R13-26-20241201","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.1840120205","article-title":"Characterization and biological properties of a hepatitis B isolated from a patient without HBV serologic markers","volume":"12","author":"Liang","year":"1990","journal-title":"HEPATOLOGY"},{"key":"R14-26-20241201","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007890-199501270-00014","article-title":"The risk of transmission of hepatitis B from HBsAg(\u2212), HBcAb(+), HBIgM(\u2212) organ donors","volume":"59","author":"Wachs","year":"1995","journal-title":"Transplantation"},{"key":"R15-26-20241201","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"R16-26-20241201","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"R17-26-20241201","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus\u2010specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J Exp Med"},{"key":"R18-26-20241201","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1172\/JCI115590","article-title":"Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion","volume":"89","author":"Tsai","year":"1992","journal-title":"J Clin Invest"},{"key":"R19-26-20241201","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","article-title":"Transient restoration of anti\u2010viral T cell responses induced by lamivudine therapy in chronic hepatitis B","volume":"39","author":"Boni","year":"2003","journal-title":"J Hepatol"},{"key":"R20-26-20241201","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1172\/JCI3731","article-title":"Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B","volume":"102","author":"Boni","year":"1998","journal-title":"J Clin Invest"},{"key":"R21-26-20241201","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of chronic hepatitis B: 2000 \u2014 Summary of a Workshop","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"key":"R23-26-20241201","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000150411","article-title":"Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S\u2010gene","volume":"38","author":"Magnius","year":"1995","journal-title":"Intervirology"},{"key":"R24-26-20241201","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0016-5085(03)00895-3","article-title":"Hepatitis B virus genotypes in the United States: results of a nationwide study","volume":"125","author":"Chu","year":"2003","journal-title":"Gastroenterology"},{"key":"R25-26-20241201","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenteroloogy"},{"key":"R26-26-20241201","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1126\/science.8211155","article-title":"From hepatitis to hepatoma: lessons from type B viral hepatitis","volume":"262","author":"Chen","year":"1993","journal-title":"Science"},{"key":"R27-26-20241201","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","author":"Lok","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-26-20241201","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1046\/j.1440-1746.2000.02097.x","article-title":"Natural history of hepatitis B infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma","volume":"15","author":"Chu","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"R29-26-20241201","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0016-5085(80)90130-4","article-title":"Seroconversion from hepatitis B e antigen to anti\u2010HBe in chronic hepatitis B virus infection","volume":"79","author":"Realdi","year":"1980","journal-title":"Gastroenterology"},{"key":"R30-26-20241201","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-94-6-744","article-title":"Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis","volume":"94","author":"Hoofnagle","year":"1981","journal-title":"Ann Intern Med"},{"key":"R31-26-20241201","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0016-5085(83)80114-0","article-title":"Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis","volume":"84","author":"Liaw","year":"1983","journal-title":"Gastroenterology"},{"key":"R32-26-20241201","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/hep.1840070424","article-title":"Chronic type B hepatitis and the \u201chealthy\u201d HBsAg carrier state","volume":"7","author":"Hoofnagle","year":"1987","journal-title":"HEPATOLOGY"},{"key":"R33-26-20241201","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-118-3-199302010-00006","article-title":"The natural history of asymptomatic hepatitis B surface antigen carriers","volume":"118","author":"De Franchis","year":"1993","journal-title":"Ann Intern Med"},{"key":"R34-26-20241201","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.gastro.2004.06.021","article-title":"Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years","volume":"127","author":"Manno","year":"2004","journal-title":"Gastroenterology"},{"key":"R35-26-20241201","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long\u2010term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R36-26-20241201","first-page":"7","article-title":"Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment","volume":"1","author":"Hadziyannis","year":"1995","journal-title":"Viral Hep Rev"},{"key":"R37-26-20241201","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","article-title":"Mutation preventing formation of e antigen in patients with chronic HBV infection","volume":"2","author":"Carman","year":"1989","journal-title":"Lancet"},{"key":"R38-26-20241201","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/hep.510290352","article-title":"Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion","volume":"29","author":"Chan","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R39-26-20241201","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0016-5085(84)90406-2","article-title":"Spontaneous reactivation of chronic type B hepatitis","volume":"86","author":"Davis","year":"1984","journal-title":"Gastroenterology"},{"key":"R40-26-20241201","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"HEPATOLOGY"},{"key":"R41-26-20241201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0676.1989.tb00405.x","article-title":"Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"9","author":"Liaw","year":"1989","journal-title":"Liver"},{"key":"R42-26-20241201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R43-26-20241201","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(03)00139-9","article-title":"Natural history of hepatitis B","volume":"39","author":"Fattovich","year":"2003","journal-title":"J Hepatol"},{"key":"R44-26-20241201","first-page":"S3","article-title":"EASL International Consensus Conference on Hepatitis B;13\u201014 September 2002","volume":"39","author":"EASL","year":"2003","journal-title":"J Hepatol"},{"key":"R45-26-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"R46-26-20241201","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: Diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R47-26-20241201","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for grading activity in chronic hepatitis C","volume":"24","author":"Bedossa","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R48-26-20241201","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histologic grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R49-26-20241201","first-page":"1356","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R50-26-20241201","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cld.2005.05.009","article-title":"Use of virologic assays in the diagnosis and management of hepatitis C virus infection","volume":"9","author":"Chevaliez","year":"2005","journal-title":"Clin Liver Dis"},{"key":"R51-26-20241201","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1128\/JCM.40.6.1972-1976.2002","article-title":"Assessment of the COBAS Amplicor HBV Monitor test for quantitation of serum hepatitis B virus DNA levels","volume":"40","author":"Lopez","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R52-26-20241201","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/JCM.43.8.4251-4254.2005","article-title":"Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real\u2010time semiautomated assay","volume":"43","author":"Lindh","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R53-26-20241201","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long\u2010term follow\u2010up of HBeAg\u2010positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"key":"R54-26-20241201","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/gast.1997.v113.pm9352870","article-title":"Long\u2010term follow\u2010up of patients with chronic hepatitis B treated with interferon alfa","volume":"113","author":"Lau","year":"1997","journal-title":"Gastroenterology"},{"key":"R55-26-20241201","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long\u2010term follow\u2010up of alpha\u2010interferon treatment of patients with chronic hepatitis B","volume":"39","author":"van Zonneveld","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R56-26-20241201","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/0016-5085(93)91082-S","article-title":"Long\u2010term follow\u2010up of chronic hepatitis B patients treated with interferon alpha","volume":"105","author":"Lok","year":"1993","journal-title":"Gastroenterology"},{"key":"R57-26-20241201","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine is not durable in patients with chronic hepatitis B in Korea","volume":"32","author":"Song","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R58-26-20241201","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha\u2010interferon treatment in patients with hepatitis B e antigen\u2010positive chronic hepatitis B: a meta\u2010analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"R59-26-20241201","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alfa\u20102a (40 kD): an advance in the treatment of hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"R60-26-20241201","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa\u20102a, lamivudine and the combination for HBeAg\u2010positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R61-26-20241201","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon afla\u20102a alone, lamivudine alone, and the two in combination in patients with HBeAg\u2010negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"R62-26-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa 2b alone or in combination with lamivudine for HBeAg\u2010positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"R63-26-20241201","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"R64-26-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one\u2010year trial of lamivudine for chronic hepatitis B","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"R65-26-20241201","first-page":"222A","article-title":"Two\u2010year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine","volume":"44","author":"Lai","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R66-26-20241201","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A double\u2010blind placebo\u2010controlled study of emtricitabine in chronic hepatitis B","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"key":"R67-26-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R68-26-20241201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen\u2010negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"R69-26-20241201","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Long\u2010term therapy with adefovir dipivoxil for HBeAg\u2010negative chronic hepatitis B","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"R70-26-20241201","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A randomized comparison of entecavir to lamivudine for treatment of HBeAg\u2010positive chronic hepatitis B in nucleoside\u2010na\u00efve patients","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"R71-26-20241201","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir for HBeAg\u2010negative chronic hepatitis B. A randomized comparison of entecavir to lamivudine for treatment of HBeAg\u2010negative chronic hepatitis B in nucleoside\u2010na\u00efve patients","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"R72-26-20241201","first-page":"714","article-title":"Mutation in HBV RNA\u2010dependent DNA polymerase confers resistance to lamivudine in vivo","volume":"24","author":"Tipples","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R73-26-20241201","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.510240339","article-title":"Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine","volume":"24","author":"Ling","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R74-26-20241201","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2005-915645","article-title":"Molecular virology and the development of resistant mutants: implications for therapy","volume":"25","author":"Locarnini","year":"2005","journal-title":"Seminars Liver Disease"},{"key":"R75-26-20241201","first-page":"67","article-title":"Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B","volume":"12","author":"Liaw","year":"2001","journal-title":"Antivir Chem Chemother"},{"key":"R76-26-20241201","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/jhep.2001.27220","article-title":"Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full\u2010length viral sequences","volume":"34","author":"Liu","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R77-26-20241201","article-title":"Antiviralresistant HBV: standardization of nomenclature and assays and recommendations for management.","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R78-26-20241201","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939759","article-title":"In vitro models for studying hepatitis B virus drug resistance","volume":"26","author":"Zoulim","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R79-26-20241201","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1172\/JCI5882","article-title":"Susceptibility of lamivudine\u2010resistant hepatitis B virus to other reverse transcriptase inhibitors","volume":"103","author":"Ono\u2010Nita","year":"1999","journal-title":"J Clin Invest"},{"key":"R80-26-20241201","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir\u2010resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R81-26-20241201","first-page":"246A","article-title":"Molecular modeling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations","volume":"40","author":"Bartholomeusz","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R82-26-20241201","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.10.018","article-title":"Virologic response and resistance to adefovir in patients with chronic hepatitis B","volume":"44","author":"Fung","year":"2006","journal-title":"J Hepatol"},{"key":"R83-26-20241201","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","article-title":"Evolution of multi\u2010drug resistant hepatitis B virus during sequential therapy","volume":"44","author":"Yim","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R84-26-20241201","first-page":"573A","article-title":"Entecavir two year resistance update: no resistance observed in nucleoside na\u00efve patients and low frequency resistance emergence in lamivudine refractory patients","volume":"42","author":"Colonno","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R85-26-20241201","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/JCM.38.2.702-707.2000","article-title":"Line probe assay for monitoring drug resistance in hepatitis B virus\u2010infected patients during antiviral therapy","volume":"38","author":"Stuyver","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R86-26-20241201","first-page":"1425","article-title":"HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C","volume":"36","author":"Wai","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R87-26-20241201","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with peg\u2010interferon alpha\u20102b for HBeAg\u2010positive chronic hepatitis B: HBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R88-26-20241201","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0016-5085(03)00700-5","article-title":"Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil","volume":"125","author":"Westland","year":"2003","journal-title":"Gastroenterology"},{"key":"R89-26-20241201","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1053\/jhep.2000.17912","article-title":"Long\u2010term therapy of chronic hepatitis B with lamivudine","volume":"32","author":"Lau","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R90-26-20241201","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"R91-26-20241201","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/135965350400900208","article-title":"No benefit to continue lamivudine therapy after emergence of YMDD mutations","volume":"9","author":"Liaw","year":"2004","journal-title":"Antivir Ther"},{"key":"R92-26-20241201","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.20374","article-title":"A dose finding study of once\u2010daily oral telbivudine in HBeAg\u2010positive patients with chronic hepatitis B virus infection","volume":"40","author":"Lai","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R93-26-20241201","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1\u2010year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen\u2010positive chronic hepatitis B","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"R94-26-20241201","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa051214","article-title":"Variant of hepatitis B virus with primary resistance to adefovir","volume":"27","author":"Schildgen","year":"2006","journal-title":"N Engl J Med"},{"key":"R95-26-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine\u2010resistant chronic hepatitis B","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"R96-26-20241201","first-page":"591A","article-title":"A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2\u2010year analysis of 604 patients","volume":"42","author":"Lampertico","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R97-26-20241201","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","article-title":"Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus","volume":"126","author":"Perrillo","year":"2004","journal-title":"Gastroenterology"},{"key":"R98-26-20241201","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.21189","article-title":"Increased risk of adefovir resistance in patients with lamivudine\u2010resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy","volume":"43","author":"Lee","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R99-26-20241201","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir","volume":"41","author":"Brunelle","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R100-26-20241201","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Gallant","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R101-26-20241201","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1086\/345770","article-title":"Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus\/hepatitis B virus\u2010coinfected individuals for whom interferon\u2010alpha and lamivudine therapy have failed","volume":"186","author":"Ristig","year":"2002","journal-title":"J Infect Dis"},{"key":"R102-26-20241201","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200301093480218","article-title":"Tenofovir disoproxil fumarate in patients with HIV and lamivudine\u2010resistant hepatitis B virus","volume":"348","author":"Benhamou","year":"2003","journal-title":"N Engl J Med"},{"key":"R103-26-20241201","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/hep.21388","article-title":"Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127","volume":"44","author":"Peters","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R104-26-20241201","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine\u2010resistant hepatitis B virus infection","volume":"40","author":"van B\u00f6mmel","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R105-26-20241201","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Tenofovir for patients with lamivudine\u2010resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy","volume":"44","author":"van B\u00f6mmel","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R106-26-20241201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8278(03)80485-3","article-title":"A randomized double\u2010blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment na\u00efve patients with chronic hepatitis B (CHB): week 52 analysis","volume":"38","author":"Sung","year":"2003","journal-title":"J Hepatol"},{"key":"R107-26-20241201","first-page":"272A","article-title":"Randomized, double\u2010blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg + chronic hepatitis B: efficacy and mechanisms of treatment response","volume":"40","author":"Lau","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R108-26-20241201","first-page":"693A","article-title":"Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine\u2010resistant patients with HBeAg\u2010negative chronic hepatitis B","volume":"44","author":"Lampertico","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R109-26-20241201","first-page":"558A","article-title":"Combination of adefovir dipivoxil with lamivudine vs. adefovir alone in lamivudine\u2010resistant HBeAg\u2010negative chronic hepatitis B patients","volume":"44","author":"Rapti","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R110-26-20241201","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/hep.20939","article-title":"Colombo. Adefovir rapidly suppresses hepatitis B in HBeAg\u2010negative patients developing genotypic resistance to lamivudine","volume":"42","author":"Lampertico","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R111-26-20241201","first-page":"591A","article-title":"A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2\u2010year analysis of 604 patients","volume":"42","author":"Lampertico","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R112-26-20241201","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0016-5085(98)70318-X","article-title":"Interferon alfa therapy for chronic hepatitis B in children: a multi\u2010national randomized controlled trial","volume":"114","author":"Sokal","year":"1998","journal-title":"Gastroenterology"},{"key":"R113-26-20241201","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","article-title":"Clinical trial of lamivudine in children with chronic hepatitis B","volume":"346","author":"Jonas","year":"2002","journal-title":"N Engl J Med"},{"key":"R114-26-20241201","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hep.21020","article-title":"Long\u2010term lamivudine therapy for children with HBeAg\u2010positive chronic hepatitis B","volume":"43","author":"Sokal","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R115-26-20241201","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2005.09.020","article-title":"Combined lamivudine\/ interferon\u2010\u03b1 treatment in \u201cimmunotolerant\u201d children perinatally infected with hepatitis B: a pilot study","volume":"148","author":"D'Antiga","year":"2006","journal-title":"J Pediatr"},{"key":"R116-26-20241201","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/hep.21077","article-title":"Chronic hepatitis B in children after e antigen seroclearance: final report of a 29\u2010year longitudinal study","volume":"43","author":"Bortolotti","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R117-26-20241201","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States","volume":"54","author":"Mast","year":"2005","journal-title":"Morb Mortal Wkly Rep"},{"key":"R118-26-20241201","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2893.1997.00072.x","article-title":"Recombinant interferon\u2010alpha therapy for acute hepatitis B: a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"4","author":"Tassopoulos","year":"1997","journal-title":"J Viral Hepat"},{"key":"R119-26-20241201","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1386-6346(02)00009-8","article-title":"Effectiveness and long\u2010term outcome of lamivudine therapy for acute hepatitis B","volume":"24","author":"Torii","year":"2002","journal-title":"Hepatol Res"},{"key":"R120-26-20241201","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2893.2004.00504.x","article-title":"The use of lamivudine for patients with acute hepatitis B (a series of cases)","volume":"11","author":"Kondili","year":"2004","journal-title":"J Viral Hepat"},{"key":"R121-26-20241201","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1478-3231.2004.0983.x","article-title":"Lamivudine treatment for acute severe hepatitis B: a pilot study","volume":"24","author":"Schmilovitz\u2010Weiss","year":"2004","journal-title":"Liver International"},{"key":"R122-26-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-8278(05)81942-7","article-title":"Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B compared to historic control at one center","volume":"42","author":"Tillmann","year":"2005","journal-title":"J Hepatol"},{"key":"R123-26-20241201","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2006-947298","article-title":"Viral hepatitis and liver transplantation","volume":"26","author":"Sharma","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R124-26-20241201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/lt.20492","article-title":"Management of the hepatitis B virus in liver transplantation setting: a European and an American Perspective","volume":"11","author":"Terrault","year":"2005","journal-title":"Liver Transpl"},{"key":"R125-26-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"AASLD Practice Guidelines: Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R126-26-20241201","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/0016-5085(93)90281-G","article-title":"Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B","volume":"104","author":"Hoofnagle","year":"1993","journal-title":"Gastroenterology"},{"key":"R127-26-20241201","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0016-5085(95)90401-8","article-title":"Low\u2010dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus","volume":"109","author":"Perrillo","year":"1995","journal-title":"Gastroenterology"},{"key":"R128-26-20241201","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multicenter United States\u2010Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B","volume":"33","author":"Perrillo","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R129-26-20241201","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"key":"R130-26-20241201","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8278(00)80371-2","article-title":"Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection","volume":"33","author":"Yao","year":"2000","journal-title":"J Hepatol"},{"key":"R131-26-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R132-26-20241201","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.510280241","article-title":"Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin","volume":"28","author":"Markowitz","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R133-26-20241201","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0168-8278(01)00089-7","article-title":"Lamivudine and low\u2010dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection","volume":"34","author":"Rosenau","year":"2001","journal-title":"J Hepatol"},{"key":"R134-26-20241201","first-page":"741","article-title":"Combination low\u2010dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post\u2010transplantation hepatitis B","volume":"6","author":"Angus","year":"2001","journal-title":"Liver Transpl"},{"key":"R135-26-20241201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/jhep.2000.8626","article-title":"Adefovir dipivoxil for the treatment of lamivudine\u2010resistant hepatitis B mutants","volume":"32","author":"Perrillo","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R136-26-20241201","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"R137-26-20241201","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"},{"key":"R138-26-20241201","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV\u20101, hepatitis B virus, and risk of liver\u2010related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"R139-26-20241201","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","article-title":"Survival in patients with HIV infection and viral hepatitis B or C: a cohort study","volume":"18","author":"Bonacini","year":"2004","journal-title":"AIDS"},{"key":"R140-26-20241201","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end\u2010stage liver disease in patients with HIV infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R141-26-20241201","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00126334-200007010-00003","article-title":"Mortality for liver disease in patients with HIV infection: a cohort study","volume":"24","author":"Puoti","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R142-26-20241201","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liverrelated deaths in persons infected with the human immunodeficiency virus. The D:A:D Study.","volume":"166","year":"2006","journal-title":"Arch Intern Med"},{"key":"R143-26-20241201","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","article-title":"Characteristics of drug resistant HBV in an international collaborative study of HIV\u2010HBV\u2010infected individuals on extended lamivudine therapy","volume":"20","author":"Matthews","year":"2006","journal-title":"AIDS"},{"key":"R144-26-20241201","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","article-title":"An open\u2010label study of tenofovir in HIV\u20101 and hepatitis B virus coinfected individuals","volume":"17","author":"Nelson","year":"2003","journal-title":"AIDS"},{"key":"R145-26-20241201","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1097\/00002030-200411190-00014","article-title":"Successful therapy of hepatitis B with tenofovir in HIV\u2010infected patients failing previous adefovir and lamivudine treatment","volume":"18","author":"Schildgen","year":"2004","journal-title":"AIDS"},{"key":"R146-26-20241201","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1086\/380398","article-title":"Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy\u2010na\u00efve and \u2010experienced patients coinfected with HIV\u20101 and hepatitis B virus","volume":"189","author":"Dore","year":"2004","journal-title":"J Infect Dis"},{"key":"R147-26-20241201","first-page":"1062","article-title":"Ninety\u2010six week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV\u20101 and wild type hepatitis B virus","volume":"39","author":"Bani\u2010Sadr","year":"2004","journal-title":"J Infect Dis"},{"key":"R148-26-20241201","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.aids.0000163948.62176.e7","article-title":"Care of patients with chronic hepatitis B and HIV co\u2010infection: recommendations from an HIV\u2010HBV International Panel","volume":"19","author":"Soriano","year":"2005","journal-title":"AIDS"},{"key":"R149-26-20241201","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treastment for adult HIV infection: 2006 recommendations of the International AIDS Society\u2010USA Panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R150-26-20241201","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2893.2006.00778.x","article-title":"Reduction in liver\u2010related hospital admissions and deaths in HIV\u2010infected patients since the year 2002","volume":"13","author":"Martin\u2010Carbonero","year":"2006","journal-title":"J Viral Hepat"},{"key":"R151-26-20241201","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(75)90897-1","article-title":"Fulminant hepatic failure in leukaemia and choroiocarcinoma related to withdrawal of cytotoxic drug therapy","volume":"2","author":"Galbraith","year":"1975","journal-title":"Lancet"},{"key":"R152-26-20241201","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","article-title":"Reactivation of chronic hepatitis B virus infection by cancer chemotherapy","volume":"96","author":"Hoofnagle","year":"1982","journal-title":"Ann Intern Med"},{"key":"R153-26-20241201","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J Med Virol"},{"key":"R154-26-20241201","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2893.2003.00479.x","article-title":"Lamivudine prophylaxis for prevention of chemotherapy\u2010induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies","volume":"11","author":"Idilman","year":"2004","journal-title":"J Viral Hepat"},{"key":"R155-26-20241201","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1046\/j.1365-2036.2002.01364.x","article-title":"Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients","volume":"16","author":"Lim","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R156-26-20241201","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"R157-26-20241201","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.leu.2403914","article-title":"Fulminant B hepatitis in a surface antigen\u2010negative patient with B\u2010cell chronic lymphocytic leukaemia after rituximab therapy","volume":"19","author":"Niscola","year":"2005","journal-title":"Leukemia"},{"key":"R158-26-20241201","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R159-26-20241201","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00007890-199810150-00012","article-title":"Reactivation of hepatitis B after transplantation in patients with pre\u2010existing anti\u2010hepatitis B surface antigen antibodies: report on three cases and review of the literature","volume":"66","author":"Blanpain","year":"1998","journal-title":"Transplantation"},{"key":"R160-26-20241201","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM198703053161015","article-title":"Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV","volume":"316","author":"Biggar","year":"1987","journal-title":"N Engl J Med"},{"key":"R161-26-20241201","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/158.3.666","article-title":"Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1","volume":"158","author":"Lazizi","year":"1988","journal-title":"J Infect Dis"},{"key":"R162-26-20241201","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-2036.2006.03081.x","article-title":"Systematic review: lamivudine prophylaxis for chemotherapy\u2010induced reactivation of chronic hepatitis B virus infection","volume":"24","author":"Kohrt","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R163-26-20241201","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg\u2010negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"R164-26-20241201","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007890-199809150-00012","article-title":"Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti\u2010HBs and anti\u2010HBc","volume":"66","author":"Dhedin","year":"1998","journal-title":"Transplantation"},{"key":"R165-26-20241201","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1034\/j.1600-0609.2000.9l228.x","article-title":"Reactivation of hepatitis B virus infection in an anti\u2010HBc and anti\u2010HBs positive patient after allogeneic bone marrow transplantation","volume":"65","author":"Nordbo","year":"2000","journal-title":"Eur J Haematol"},{"key":"R166-26-20241201","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1080\/1042819021000033042","article-title":"Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation","volume":"43","author":"Goyama","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R167-26-20241201","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jmv.20705","article-title":"Lamivudine prophylaxis and treatment of hepatitis B virus\u2010exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab","volume":"78","author":"Moses","year":"2006","journal-title":"J Med Virol"},{"key":"R168-26-20241201","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","article-title":"Hepatitis B reactivation after withdrawal of pre\u2010emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy","volume":"54","author":"Hui","year":"2005","journal-title":"Gut"},{"key":"R169-26-20241201","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/hupa.2001.25586","article-title":"Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion","volume":"32","author":"Tanji","year":"2001","journal-title":"Hum Pathol"},{"key":"R170-26-20241201","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000441-200212000-00011","article-title":"Rapid communication: acute renal failure associated with tenofovir: evidence of drug\u2010induced nephrotoxicity","volume":"24","author":"Coca","year":"2002","journal-title":"Am J Med Sci"},{"key":"R171-26-20241201","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjmed.2004.03.025","article-title":"Tenofovir\u2010associated nephrotoxicity: Fanconi syndrome and renal failure","volume":"117","author":"Rifkin","year":"2004","journal-title":"Am J Med"},{"key":"R173-26-20241201","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","article-title":"Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double\u2010blind, randomized, placebo\u2010controlled studies","volume":"66","author":"Izzedine","year":"2004","journal-title":"Kidney Int"},{"key":"R174-26-20241201","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-1293.2005.00318.x","article-title":"The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy","volume":"6","author":"Parsonage","year":"2005","journal-title":"HIV Med"},{"key":"R175-26-20241201","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00042560-199904010-00001","article-title":"Administration of 9\u2010[2\u2010(R)\u2010(phosphonomethoxy)propyl] adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatto): safety and efficacy studies","volume":"20","author":"Tarantal","year":"1999","journal-title":"J Acquir Immune Defic Syndr Human Retrovirol"},{"key":"R176-26-20241201","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R177-26-20241201","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3748\/wjg.v10.i6.910","article-title":"Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy","volume":"10","author":"Su","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R178-26-20241201","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1365-2893.2003.00440.x","article-title":"Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection","volume":"10","author":"van Zonneveld","year":"2003","journal-title":"J Viral Hepat"},{"key":"R179-26-20241201","first-page":"47","article-title":"Entecavir (Baraclude) for chronic hepatitis B.","volume":"47","year":"2005","journal-title":"Med Lett Drugs Therapeut"},{"key":"R181-26-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350601100113","article-title":"Novel approaches to new therapies for hepatitis B virus infection","volume":"11","author":"Loomba","year":"2006","journal-title":"Antivir Ther"},{"key":"R182-26-20241201","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug\u2010induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"R183-26-20241201","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","article-title":"Inhibition of human hepatitis B virus replication by AT\u201061, a phenylpropenamide derivative, alone and in combination with (\u2212)beta\u2010L\u20102\u2032,3\u2032\u2010dideoxy\u20103\u2032\u2010thiacytidine","volume":"42","author":"King","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R184-26-20241201","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1073\/pnas.92.6.2194","article-title":"Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus","volume":"92","author":"Dyson","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R185-26-20241201","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1172\/JCI200113787","article-title":"X\u2010deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo","volume":"108","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"R186-26-20241201","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nbt824","article-title":"Inhibition of hepatitis B virus in mice by RNA interference","volume":"21","author":"McCaffrey","year":"2003","journal-title":"Nat Biotechnol"},{"key":"R187-26-20241201","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2005","journal-title":"Nature"},{"key":"R188-26-20241201","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","article-title":"Interleukin\u201010 determines viral clearance or persistence in vivo","volume":"12","author":"Brooks","year":"2006","journal-title":"Nat Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21627","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200704000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:01:50Z","timestamp":1733058110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200704000-00026"}},"subtitle":["Summary of a clinical research workshop\u2020"],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":184,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21627","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}